NasdaqGS:ACADBiotechs
Acadia R&D Chief Plans Retirement As Company Stresses Pipeline Continuity
Acadia Pharmaceuticals (NasdaqGS:ACAD) announced the planned retirement of its Head of Research and Development, Dr. Elizabeth H.Z. Thompson.
Dr. Thompson is expected to transition from her current role and remain with the company as a consultant through at least the end of 2026.
Her consulting role is intended to support continuity around a key Phase 2 clinical readout in Alzheimer's disease psychosis and early Phase 3 planning.
Acadia focuses on central nervous system conditions, where...